Nuvation Bio Inc.
Financials
Valuation Metrics
Nuvation Bio Inc.'s Market Cap is $2.12B. At end of 2025 it was $3.09B. Ranked #1984 of 3,121 in US market (top 64%), #1229 of 1,658 on NYSE (top 74%), #133 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.12B | US#1,984/3,121 Sec#133/266 |
| Revenue | $170M | US#2,610/3,121 Sec#114/266 |
| Net Income | $-150M | US—/3,121 Sec—/266 |
| Total Assets | $745M | US#2,604/3,121 Sec#126/266 |
| Net Assets | $254M | US#2,593/3,121 Sec#168/266 |
| Employees | 305 | US#2,418/3,121 Sec#109/266 |
| Value | ||
| P/B | 8.34x | US#2,548/3,121 Sec#183/266 |
| P/S | 12.47x | US#2,744/3,121 Sec#119/266 |
| FCF Yield | -3.91% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -59.02% | US#2,717/3,121 Sec#171/266 |
| ROA | -20.12% | US#2,797/3,121 Sec#128/266 |
| Op. Margin | -81.00% | US#2,718/3,121 Sec#117/266 |
| Revenue Growth | 1083.56% | US#18/3,121 Sec#10/266 |
| Financial Health | ||
| Debt Ratio | 193.27% | US#1,763/3,121 Sec#199/266 |
| Total Debt | $252M | US#2,176/3,121 Sec#89/266 |
| FCF | $-83M | US#2,601/3,121 Sec#132/266 |
| Cash | $259M | US#1,538/3,121 Sec#91/266 |
| Current Ratio | 8.37x | US#309/3,121 Sec#93/266 |
| Performance | ||
| 1Y Return | 86.60% | US#270/3,121 Sec#72/266 |
| 1M Return | -12.60% | US#2,668/3,121 Sec#204/266 |
| From 52W High | -37.61% | US#2,397/3,121 Sec#184/266 |
| 1Y MDD | -57.55% | US#2,723/3,121 Sec#207/266 |
| Trading | ||
| Volume | 5,242,306 shares | US#319/3,121 Sec#26/266 |
| Trading Value | $32M | US#1,579/3,121 Sec#122/266 |
| Per Share | ||
| EPS | $-0.43 | US—/3,121 Sec—/266 |
| BPS | $0.73 | US#2,731/3,121 Sec#211/266 |
Company Info
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.